WO2008067655A1 - Biocompatible hydrogel-based scaffolds - Google Patents
Biocompatible hydrogel-based scaffolds Download PDFInfo
- Publication number
- WO2008067655A1 WO2008067655A1 PCT/CA2007/002179 CA2007002179W WO2008067655A1 WO 2008067655 A1 WO2008067655 A1 WO 2008067655A1 CA 2007002179 W CA2007002179 W CA 2007002179W WO 2008067655 A1 WO2008067655 A1 WO 2008067655A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chitosan
- collagen
- scaffold
- scaffolds
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/003—Crosslinking of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/003—Crosslinking of starch
- C08B31/006—Crosslinking of derivatives of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
- C08H1/06—Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
- C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
- C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
Definitions
- This invention relates to biocompatible hydrogels useful as scaffolds.
- Scaffolds also known as matrices, are artificial three-dimensional structures capable of containing cells, drugs or bioactive agents, and/or fluids, such as cell growth medium. Scaffolds can serve multiple purposes including supporting three-dimensional tissue formation, allowing cell attachment and migration, delivery and retention of cells and biochemical factors, enabling diffusion of vital cell nutrients and expressed products, and exerting certain mechanical and biological influences to modify the behaviour of the cell phase.
- Scaffolds may be formed either in vitro or in situ.
- In vitro scaffolds can be prefabricated into a defined shape and architecture. Thereafter, they can, for example, be seeded with cells, and either implanted directly into the tissue of interest, or first cultured in vitro to generate new growth and then implanted into the tissue.
- scaffolds that gel in situ are more desirable.
- desired components such as cells and/or other biological materials like cell adhesive motifs and cell growth nutrients, can be combined with a liquid solution of the polymer, and injected into the desired regions, such as into irregularly shaped tissue defects. Once injected, the liquid gels (solidifies), encapsulating the cells and/or other materials within the scaffold.
- pNIPAAM-derived poly (N- isopropylacrylamide-derived (pNIPAAM-derived) systems and PEO/PPO block copolymer systems.
- pNIPAAM polymer exhibits a soluble hydrophilic state below its lower critical solution temperature (LCST), usually about 32 0 C.
- LCST lower critical solution temperature
- pNIPAAM has been grafted onto some natural polymers such as chitosan and gelatin.
- the resulting gelatin-g-pNIPAAM and chitosan-g-pNIPAAM also have a phase transition above about 32 0 C. They have shown some promising results for cell encapsulation.
- pNIPAAM is non- biodegradable and its toxicity is unknown, pNIPAAM-derived thermoresponsive biomaterials, pose problems for commercialization.
- PEO/PPO block copolymer i.e. poly (ethylene oxide-co-propylene oxide-co- polyethylene oxide) (PEO-PPO-PEO) (Commercial name: PoloxamerTM (ICI)) is water soluble and forms gels around body temperature, i.e., 37 0 C.
- PEO-PPO-PEO has been widely investigated for drug delivery and has been used in some marketed products at low molecular weight.
- PEO-PPO-PEO has not been widely used in medicine because of its toxicity (found in animal trials) and its non-biodegradability.
- Naturally occurring polymeric biomaterials such as proteins and polysaccharides, have the advantage that they generally have good biocompatibility and low immunogenicity.
- US patent 6,953,784 discloses an injectable biodegradable carrier for drug delivery, comprising a first and second polysaccharide crosslinked together, wherein the first polysaccharide is oxidized to provide the functional groups necessary for the crosslinking reaction.
- Exemplified are carriers in which the first polysaccharide is hyaluronic acid and the second polysaccharide is hyaluronic acid or chondroitin sulphate.
- US patent 6,514,522 discloses an oxidized polysaccharide, arabinogalactan, cross- linked with the polyamine, chitosan, in the form of microspheres.
- This microsphere scaffold is formed in vitro and is intended to be used in wound healing, tissue adhesion prevention, and as a surgical homeostatic material.
- US patent 5,866,165 discloses crosslinking collagen with oxidized polysaccharides such as hyaluronic acid to form a scaffold potentially useful for the repair of bone and cartilage. However, this scaffold is not particularly cannot be used as an in situ gelling scaffold.
- the present invention provides a biocompatible and biodegradable hydrogel scaffold comprising: an oxidized polysaccharide, said polysaccharide being selected from the group consisting of chondroitin sulfate, alginate, hyaluronic acid, water- soluble starch and its derivatives, and water-soluble gum and its derivatives, and an amine- containing polymer selected from collagen, chitosan, their derivatives, and a mixture thereof, crosslinked to said oxidized polysaccharide.
- the hydrogel scaffolds of the invention may be used to make in situ gels and in vitro matrices. Uses of the scaffolds include the sustained release of stem cells and bioactive molecules, such as medications and growth factors. They may also be used as matrices for the regeneration of tissue, such as corneal tissue.
- the scaffolds of the present invention may be optically clear, permitting them to be used, for Example in the cornea.
- the scaffolds of the present invention may be injectable, thus avoiding the need to perform surgery.
- hydrogel scaffolds of the invention may be preformed in vitro.
- scaffolds of the invention can be made under a wide range of pH conditions, allowing for a diversity of scaffolds to be fabricated. By varying the pH, one can affect the porosity, the interaction with cells, and the transparency of the scaffold.
- Fig. 1 is a graph showing the cell count for in vitro growth of corneal epithelial cells beside scaffolds in accordance with aspects of the present invention.
- Fig. 2 is a graph showing the swelling behaviour of scaffolds in accordance with certain aspects of the invention.
- Fig. 3 is a graph showing the in vitro growth of DRG nerves (neurites) on selected scaffolds in accordance with aspects of the present invention.
- the present invention provides a biocompatible and biodegradable hydrogel scaffold comprising (i) an oxidized polysaccharide, said polysaccharide being selected from the group consisting of chondroitin sulfate, alginate, hyaluronic acid, water- soluble starch and its derivatives, and water-soluble gum and its derivatives, and (ii) an amine-containing polymer selected from collagen, chitosan, their derivatives, and a mixture thereof, crosslinked to said oxidized polysaccharide.
- an oxidized polysaccharide said polysaccharide being selected from the group consisting of chondroitin sulfate, alginate, hyaluronic acid, water- soluble starch and its derivatives, and water-soluble gum and its derivatives
- an amine-containing polymer selected from collagen, chitosan, their derivatives, and a mixture thereof, crosslinked to said oxidized polysaccharide.
- the scaffold may gel in vitro or in situ.
- a hydrogel is a three-dimensional network of hydrophilic polymer chains that are crosslinked through either chemical or physical bonds. Because of the hydrophilic nature of polymer chains, hydrogels absorb water to swell in the presence of abundant water. By definition, water constitutes at least 10% of the total weight (or volume) of a hydrogel. When the content of water exceeds 95% of the total weight (or volume), the hydrogel is called a superabsorbent.
- the oxidized polysaccharide of the invention may be any of oxidized chondroitin sulfate, alginate, hyaluronic acid, water-soluble starch and its derivatives, or water-soluble gum and its derivatives.
- water-soluble starch includes water-soluble starches that are known to one skilled in the art. Derivatives of water-soluble starches include water-soluble starches that have been oxidized and/or PEGylated.
- water-soluble gum includes water-soluble gums that are known to one skilled in the art. Examples include xanthan gum, guar gum, dextran gum, acacia gum, carrageenan gum, locust bean gum, and scleroglucan gum. Derivatives of water-soluble gums include water-soluble gums that have been oxidized and/or PEGylated.
- the method of preparing the oxidized polysaccharide comprises opening sugar rings on the polysaccharide and oxidizing hydroxyl groups to aldehydes using a selective oxidizing agent.
- a selective oxidizing agent which oxidizes a hydroxyl group to an aldehyde, can be used, such as specific sugar oxidases, sodium periodate, and potassium periodate. In one embodiment sodium periodate or potassium periodate is used.
- the oxidizing agent is one in which a residue thereof would not be harmful to a patient or it can be easily extracted out.
- the number of aldehyde groups (AD) produced in this manner can be stoichiometrically controlled, and characterized in terms of oxidation degree (OD), given in mols AD per mol of polysaccharide.
- OD oxidation degree
- a method for determining the degree of oxidation using hydroxylamine hydrochloride titration is provided in Zhao et al., Pharmaceutical Research 8:400-402 (1991 ).
- the oxidized polysaccharide may have an OD ranging from 52 to 261 mol aldehyde per mol polysaccharide.
- OD may also be stated as % (mol AD/total mol OH) representing:
- an OD of 52 to 261 mol aldehyde per mol polysaccharide is equivalent to approximately 20 to 100% mol AD/total mol.
- Oxidizable OH groups include, for instance, adjacent OH groups. Oxidation of adjacent hydroxy! groups is known in the art (see for example, Methods in Carbohydrate Chemistry. 1962 1 : 432-435. Academic Press, New York, Ed. Whistler Wolfrom; and Johann MG Reyes et al. Invest. Ophthalmol. Vis. Sci. 2005 46: 1247-1250).
- the oxiized polysaccharide of the invention may have an OD of from 1 to 100%, preferably it has an OD of 20-100%, more preferably 80-100%.
- Higher ODs i.e. the more aldehydes
- the oxidized polysaccharide is an oxidized chondroitin sulphate, also referred to herein as chondroitin sulfate aldehyde (CS-A).
- CS-A chondroitin sulfate aldehyde
- the oxidized chondroitin sulphate is prepared by dissolving chondroitin sulphate and sodium periodate together in deionized water in the dark and allowing them to react for a period of time sufficient to achieve the desired oxidation degree (OD).
- the amine-containing polymer is collagen, chitosan, their derivatives, and a mixture thereof.
- the average molecular weight of the polymer is about 200 to 600 kDa, but lighter and heavier polymers may be used.
- the collagen may be obtained from conventional sources. It may also be a recombinant form, which is particularly useful when very high purity is desirable.
- the term collagen derivatives includes gelatin.
- Chitosan is a linear polysaccharide composed of randomly distributed beta(1 ,4) linked D-glucosamine and N-acetyl-D-glucosamine.
- the term chitosan includes both acid-soluble and water-soluble chitosan. In one embodiment, the chitosan is acid-soluble chitosan.
- Chitosan derivatives includes N,O-carboxymethyl chitosan, N-carbosymethyl chitosan, and O-carboxymethyl chitosan, and polyethylene glycol (PEG)-derivatized chitosan.
- PEG polyethylene glycol
- the amine-containing polymer may be a combination of both chitosan and collagen.
- the mass ratio of collagen to chitosan may be varied depending on the desired physical and biological characteristics of the scaffold. In one embodiment the mass ratio of collagen to chitosan ranges from 0 to 20, more preferably 1 to 8. The ratio may also be 0 to 8 or 0.5 to 8. In one aspect, the ratio is 4. Typically, if a more transparent and/or homogeneous scaffold is desired, a higher collagen to chitosan mass ratio will be used.
- Use of a combination of chitosan and collagen results in a hydrogel that has a variety of different functional sites (e.g. -COOH, -OH, -NH 2 , -CH..etc.), meaning that one has more flexibility in terms of incorporating a variety of drugs, biological agents... etc.
- the aldehyde groups on the oxidized polysaccharides are reacted with the amino groups on the amine-containing polymer, forming covalent imine crosslinks, via a Schiff-base reaction.
- the reaction proceeds by cross-linking in aqueous solution at a pH of about 3 to 10.
- the reaction may also proceed at pH 3-7.4, pH 9-10, or at a pH of 5 or 7.4.
- the ratios of oxidized polysaccharide to amine-containing polymer can be varied, depending on what physical and biological characteristics are desired. For instance the weight percentage of the oxidized polysaccharide to the amine-containing polymer may be from 5 to 100%, 15 to 95 %, 20 to 30 %, or 24%.
- this may be from about 0.01 to 12, 0.03 to 11 , 0.04 to 3.6, and about 0.75.
- Scaffolds with a low solid content or high swelling and high water content are preferred for injectable gels; they are also typically more porous.
- scaffolds with a high solid content, low swelling and low water content are preferred as skin constructs or grafts. High swelling is typically achieved by using less cross-linker (i.e. less of the oxidized polysaccharide, or using a polysaccharide with a lower OD) or using less concentrated solutions of all the reactant.
- Scaffolds with a lower weight percentage of oxidized polysacchardie to amine-containing polymer are more transparent and homogeneous.
- the transparency of the gels may be controlled.
- the transparency of the scaffold will depend on the chemical composition of the scaffold as well as the pH at which it is made. Typically, in tha basic pH range, the higher the pH, the more transparent the scaffold. All the scaffolds made at pH 9-10 shown in the following examples were clear.
- the properties of the scaffolds also will depend on the proximal conditions, whether in vitro or in situ.
- the oxidized polysaccharide and the amine-containing polymer are mixed together and transferred into a scaffold mold after mixing, and the cross- linking reaction is allowed to proceed.
- the scaffolds may cure over a period about 12 to 24 hours at room temperature and for 12 to 24 hours at 37°C.
- the scaffolds are washed to extract out any reaction by-products.
- Sodium cyanoborohydride (Na(CN)BH 3 ) was not used, as it would be toxic if any residue remained in the hydrogel.
- the oxidized polysaccharide and the amine-containing polymer are combined together with any desired materials (e.g. cells, growth factors,... etc.), maintained at a temperature well below their phase transition until injection, and then injected into the desired location.
- any desired materials e.g. cells, growth factors,... etc.
- the scaffold excludes constructs comprising hyaluronic acid and only collagen as the polyamine-containing polymer.
- the product, CS-aldehyde was obtained by lyophilization at -65°C for 8 hrs.
- the determination of the degree of oxidation was performed by hydroxylamine hydrochloride titration (H. Zhao et al., Pharmaceutical Research, 8: 400- 402 (1991 )).
- the OD was determined as 52 mol AD/mol CS.
- Example 1.2 Synthesis of chondroitin sulfate aldehyde with an OD of 94 mol AD/mol CS (CS-A-94): Two grams of chondroitin sulfate C (CS, Sigma-Aldrich) and 2 g of sodium periodate (NaIO 4 , Sigma-Aldrich) were dissolved together in 33 ml of deionized water and were protected from light. The reaction was processed as for Example 1.1. The OD was determined as 94 mol AD/mol CS.
- Example 1.3 Synthesis of Chondroitin Sulfate Aldehyde with an OD of 261 mol AD/mol CS (CS-A-261): Two grams of chondroitin sulfate C (CS, Sigma-Aldrich) and 4 g of sodium periodate (NaIO 4 , Sigma-Aldrich) were dissolved together in 33 ml of deionized water and were protected from light. The reaction was processed as for Example 1.1. The OD was determined as 261 mol AD/mol CS.
- amine-containing polymers Solutions of amine-containing polymers were prepared. Chitosan solutions were prepared containing 2-10% (w/v) chitosan by dissolving chitosan flakes (M w 40OkDa obtained from Fluka) in 0.2 N hydrochloric acid (HCI) and stirring at 4 0 C. Collagen solutions were prepared containing 1-20% (w/v) collagen type I; freeze dried porcine collagen powder that was obtained from Nippon Meat Packers, lnc (Japan) was dissolved in cold water (sterile dd H 2 O) and stirred at 4°C.
- HCI hydrochloric acid
- Mixtures of chitosan and collagen were prepared by mixing the above mentioned solutions of chitosan and collagen together in a syringe system at predetermined ratios to make a homogeneous blend containing 2-10% (w/v) chitosan and 1-20% (w/v) collagen type I.
- Various scaffolds in accordance with aspects of the invention are shown in Table 1.
- the w/v %'s given for the acid-soluble chitosan and the collagen columns refer to pre-mixing %'s.
- the collagen to chitosan mass ratio refers to the ratios upon mixing and throughout the crosslinking reaction.
- the amine-containing polymers were cross-linked using chondroitin sulfate aldehyde (CS-A).
- CS-A chondroitin sulfate aldehyde
- the 200 series scaffolds (collagen concentration ranges from 2-20% w/v) were prepared by mixing the amine-containing polymer with the oxidized polysaccharide (the crosslinker) at a pH of about 3 using 0.6 M 2-(N-Morpholino) ethanesulfunic acid (MES) buffer or a pH of about 5 to 7.4 using sodium hydroxide or various concentrations of phosphate buffered saline (PBS).
- the 300 series scaffolds (collagen concentration is 1% w/v) were prepared as described.
- Example 2.1 Preparation of BCI-206 scaffold: 1 ml of 5% chitosan solution was transferred to a 2.5 ml Luer tip glass syringe. The chitosan solution was then mixed with 0.3 ml MES buffer using a plastic Tefzel Tee-piece. The mixture was then mixed with 0.0181 g CS-A-261 cross-linker agent [CS-A to chitosan mass ratio of 0.31] that was dissolved in 0.2 ml MES buffer, at about 0°C-4°C. The components were thoroughly mixed by repeated pumping action between the first and second syringes through the Tee. This process was performed under iced water to prevent premature crosslinking and air bubbles formation and entrapment.
- the homogeneous mixture was immediately dispensed into 500 microns glass flat moulds (or plastic in vitro moulds) and cured first at room temperature for 24 hours, and then at 37 0 C for 24 hours, in 100% humidity environments at both temperatures.
- Each final scaffold sample was carefully separated from its mould after immersion in phosphate buffered saline (PBS) for 1 hour.
- PBS solution (0.5% in PBS, containing 1 % chloroform
- Example 2.2 Preparation of BCI-207 scaffold: This scaffold was prepared as for Example 2.1 using 1 ml of 5% chitosan solution and 0.0091 g CS-A-261 cross-linker agent [CS-A to chitosan mass ratio of 0.18].
- Example 2.3 Preparation of BCI-210 scaffold: This scaffold was prepared as for Example 2.1 using 1 ml of 5% chitosan solution and 0.0091 g CS-A-52 cross-linker agent [CS-A to chitosan mass ratio of 0.18].
- Example 2.4 Preparation of BCI-211 scaffold: 0.5 ml of 5% chitosan solution was added to 0.25 ml of a 4% collagen solution [collagen:chitosan mass ratio of 0.5] in a 2.5 ml Luer tip glass syringe. The composition was then mixed with 0.35 ml MES buffer (or PBS buffer) using a plastic TefzelTM Tee-piece. The mixture was then mixed with 0.0141 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.47] that was dissolved in 0.35 ml MES buffer (or PBS buffer), at about 0°C-4°C. The remainder of the reaction was processed as for Example 2.1.
- Example 2.5 Preparation of BCI-212 scaffold: This scaffold was prepared as for Example 2.4 using 0.25 ml of 5% chitosan solution and 0.5 ml of a 4% collagen solution [collagen:chitosan mass ratio of 2.0] and 0.0072 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.18].
- Example 2.4 using 0.5 ml of 5% chitosan solution and 0.25 ml of a 4% collagen solution [collagen:chitosan mass ratio of 0.5] and 0.0282 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.94], which was synthesized according to Example 1.3.
- Example 2.4 using 0.25 ml of 5% chitosan solution and 0.5 ml of a 4% collagen solution [collagen:chitosan mass ratio of 2.0] and 0.0145 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.51].
- Example 2.8 Preparaton of BCI-217 scaffold: 0.7 ml of 4% collagen solution was transferred to a 2.5 ml Luer tip glass syringe. The collagen solution was then mixed with 0.3 ml MES buffer using a plastic Tefzel Tee-piece. The mixture was then mixed with 0.0193 g CSA-261 cross-linker agent [CSA to collagen mass ratio of 0.69] that was dissolved in 0.3 ml MES buffer, at about 0°C-4°C. The remainder of the reaction was processed as for Example 2.1.
- Example 2.9 Preparation of BCI-218 scaffold: 0.17 ml of 5% chitosan solution was added to 0.75 ml of a 4% collagen solution [collagen:chitosan mass ratio of 4.2] in a 2.5 ml Luer tip glass syringe. The composition was then mixed with 0.3 ml MES buffer (or PBS buffer) using a plastic Tefzel Tee-piece. The mixture was then mixed with 0.0089 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.24] that was dissolved in 0.3 ml MES buffer (or PBS buffer), at about 0°C-4°C. The remainder of the reaction was processed as for Example 2.1.
- Example 2.10 Preparation of BC I -221 scaffold: This scaffold was prepared as for Example 2.9 using 0.145 ml of 3% chitosan solution and 0.75 ml of a 2% collagen solution [collagen:chitosan mass ratio of 4.2] and 0.0092 g CSA-261 cross-linker agent [CSA to chitosan/collagen mass ratio of 0.49].
- Example 2.11 Preparation of BCI-222 scaffold: This scaffold was prepared as for Example 2.9 using 0.3 ml of 5% chitosan solution and 0.50 ml of a 20% collagen solution [collagen:chitosan mass ratio of 8.0] and 0.0184 g CSA-261 cross-linker agent [CSA to chitosan/collagen mass ratio of 0.16].
- Example 3.1 Preparation of BCI-300 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial. This vial was cooled on ice for 30min. 200 ⁇ l of CSA-52 (12 mg CSA/ml water) was added causing a translucent gel to be formed. The final pH of the mixture was 4. The gel was incubated for a further 15h at room temperature and washed with water.
- Example 3.2 Preparation of BCI-301 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial. This vial was cooled on ice for 30min. 50 ⁇ l of CSA-52 (12mg CSA/ml water) was added causing a translucent gel to be formed. The final pH of the mixture was 4. The gel was incubated for a further 15h at room temperature and washed with water.
- Example 3.3 Preparation of BCI-302 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial, and this vial was cooled on ice for 30min. Then 10 ⁇ l NaOH (2N) was added and mixed. 200 ⁇ l of CSA-52 (12mg CSA/ml water) was added, forming a transparent gel. The final pH of the gelling mixture was 10. The gel was incubated for a further 15h at room temperature and then washed with water overnight.
- Example 3.4 Preparation of BCI-303 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial, and the vial was cooled on ice for 30min. 10 ⁇ l NaOH (2N) was added and mixed. Then, 30 ⁇ l of CSA-94 (22.67mg CSA/ml water) was added forming a transparent gel. The final pH of the gelling mixture was 10. The gel was incubated for a further 15h at room temperature and then washed with water overnight.
- Example 3.5 Preparation of BC I -304 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial, and the vial was cooled on ice for 30min.
- Table 1 Summary of compositions for chitosan/collagen/cs.ald scaffolds
- NPM Collagen suppliers name: Nippon Meat Packers, Inc, Japan * CS-ald: Chondroitin sulfate aldehyde OD: Oxidation degree (mole CHOs per mole CS) : CHO to NH 2 molar ratio: The NH 2 refers to the total amount of calculated NH 2 in chitosan and the NH 2 of lysine residuals in collagen
- Human corneal epithelial cells (passage #1235) were seeded at a density of 5x10 3 cells per scaffold in KSFM culture medium (Invitrogen Cat# 17005-042) supplemented with 1x penicillin/streptomycin (Sigma Cat# P4333). Cultures were photographed on Days 2, 4 and 7 post-seeding. Quantified results were obtained by analyzing all photographs. An area of scaffold was selected for counting, and viable-looking cells within that area were counted using Northern Eclipse 6.0 software. The number of cells counted was normalized to the area of scaffold selected, and multiplied by a constant. The counts were expressed as cells per unit surface area.
- DAPI nuclei 4'-6-Diamidino- 2-phenylindole
- the number of epithelial cells beside the scaffolds were quantified for days two, four, and seven post-seeding and shown in Figure 1. As we can see in this Figure, growth rate of the cells was found to be similar and comparable to the control. A confluent epithelium was observed for all scaffolds and control on day 7.
- Example 5 Water Uptake (Swelling) Test: The scaffolds were tested to determine their swelling properties with respect to a PBS solution. The swelling behaviour of the scaffolds was measured by swelling the dry scaffolds in phosphate buffered saline (1 % PBS) media. Scaffolds were dried by placing them in cold chamber purged by filtered dry air at 4 0 C. Pre- weighed dry hydrogel films were then immersed in buffer solutions at pH 7.4 at room temperature. The immersion time was 24 hrs. The films were withdrawn from the solution and their wet weights were determined after first blotting with a filter paper to remove the surface water and immediately weighing the films. The swelling ratio was calculated using the equation:
- the crosslinking index (Cl) was defined and calculated from the following equation:
- Cl represents the cross-linking Index or extend of crosslinking.
- Example 6 Evaluation of surface neurite extension of dorsal root ganglia (DRG) on scaffolds: Selected scaffolds were tested for in vitro biocompatibility to nerve cells using dorsal root ganglia (DRG) from chick embryos (E 8.0). DRGs were isolated from 8 day old chick embryos and adhered to the surface of washed hydrogels with collagen matrix. DRGs were then covered with DRG medium. Neuhtes were grown for a total of 7 days, with DRG medium being changed for every 2 days.
- DRG dorsal root ganglia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Biocompatible scaffolds are disclosed which comprise an oxidized polysaccharide selected from the group consisting of chondroitin sulfate, alginate, hyaluronic acid, water-soluble starch and its derivatives, and water-soluble gum and its derivatives, and an amine-containing polymer selected from collagen, chitosan, their derivatives, and a mixture thereof, crosslinked to said oxidized polysaccharide.
Description
BIOCOMPATIBLE HYDROGEL-BASED SCAFFOLDS
FIELD OF THE INVENTION
This invention relates to biocompatible hydrogels useful as scaffolds.
BACKGROUND OF THE INVENTION
During the last two decades, significant advances have been made in the development of biocompatible and biodegradable materials for biomedical and tissue engineering applications. One such application is the development of scaffolds. Scaffolds, also known as matrices, are artificial three-dimensional structures capable of containing cells, drugs or bioactive agents, and/or fluids, such as cell growth medium. Scaffolds can serve multiple purposes including supporting three-dimensional tissue formation, allowing cell attachment and migration, delivery and retention of cells and biochemical factors, enabling diffusion of vital cell nutrients and expressed products, and exerting certain mechanical and biological influences to modify the behaviour of the cell phase.
Scaffolds may be formed either in vitro or in situ. In vitro scaffolds can be prefabricated into a defined shape and architecture. Thereafter, they can, for example, be seeded with cells, and either implanted directly into the tissue of interest, or first cultured in vitro to generate new growth and then implanted into the tissue. For some applications scaffolds that gel in situ (which includes in vivo) are more desirable. With in situ gelling scaffolds, desired components, such as cells and/or other biological materials like cell adhesive motifs and cell growth nutrients, can be combined with a liquid solution of the polymer, and injected into the desired regions, such as into irregularly shaped tissue defects. Once injected, the liquid gels (solidifies), encapsulating the cells and/or other materials within the scaffold.
Some of the most promising systems for in situ gelling are poly (N- isopropylacrylamide-derived (pNIPAAM-derived) systems and PEO/PPO block copolymer systems. pNIPAAM polymer exhibits a soluble hydrophilic state below its lower critical solution temperature (LCST), usually about 320C. pNIPAAM has been grafted onto some natural polymers such as chitosan and gelatin. The resulting gelatin-g-pNIPAAM and chitosan-g-pNIPAAM, also have a phase transition above about 320C. They have shown some promising results for cell encapsulation. However, because pNIPAAM is non-
biodegradable and its toxicity is unknown, pNIPAAM-derived thermoresponsive biomaterials, pose problems for commercialization.
PEO/PPO block copolymer, i.e. poly (ethylene oxide-co-propylene oxide-co- polyethylene oxide) (PEO-PPO-PEO) (Commercial name: Poloxamer™ (ICI)) is water soluble and forms gels around body temperature, i.e., 370C. PEO-PPO-PEO has been widely investigated for drug delivery and has been used in some marketed products at low molecular weight. However, PEO-PPO-PEO has not been widely used in medicine because of its toxicity (found in animal trials) and its non-biodegradability.
Naturally occurring polymeric biomaterials, such as proteins and polysaccharides, have the advantage that they generally have good biocompatibility and low immunogenicity. US patent 6,953,784 discloses an injectable biodegradable carrier for drug delivery, comprising a first and second polysaccharide crosslinked together, wherein the first polysaccharide is oxidized to provide the functional groups necessary for the crosslinking reaction. Exemplified are carriers in which the first polysaccharide is hyaluronic acid and the second polysaccharide is hyaluronic acid or chondroitin sulphate.
US patent 6,514,522 discloses an oxidized polysaccharide, arabinogalactan, cross- linked with the polyamine, chitosan, in the form of microspheres. This microsphere scaffold is formed in vitro and is intended to be used in wound healing, tissue adhesion prevention, and as a surgical homeostatic material. US patent 5,866,165 discloses crosslinking collagen with oxidized polysaccharides such as hyaluronic acid to form a scaffold potentially useful for the repair of bone and cartilage. However, this scaffold is not particularly cannot be used as an in situ gelling scaffold.
SUMMARY OF THE INVENTION
It is desirable to develop a polymer in the form of a hydrogel that is useful as a scaffold.
In a first aspect, the present invention provides a biocompatible and biodegradable hydrogel scaffold comprising: an oxidized polysaccharide, said polysaccharide being selected from the group consisting of chondroitin sulfate, alginate, hyaluronic acid, water- soluble starch and its derivatives, and water-soluble gum and its derivatives, and an amine- containing polymer selected from collagen, chitosan, their derivatives, and a mixture thereof, crosslinked to said oxidized polysaccharide.
The hydrogel scaffolds of the invention may be used to make in situ gels and in vitro matrices. Uses of the scaffolds include the sustained release of stem cells and bioactive molecules, such as medications and growth factors. They may also be used as matrices for the regeneration of tissue, such as corneal tissue. In one aspect the scaffolds of the present invention may be optically clear, permitting them to be used, for Example in the cornea.
In one aspect, the scaffolds of the present invention may be injectable, thus avoiding the need to perform surgery. In another aspect, hydrogel scaffolds of the invention may be preformed in vitro. Advantageously, in certain aspects, scaffolds of the invention can be made under a wide range of pH conditions, allowing for a diversity of scaffolds to be fabricated. By varying the pH, one can affect the porosity, the interaction with cells, and the transparency of the scaffold.
Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
Embodiments of the present invention will now be described, by way of Example only, with reference to the attached Figures, wherein:
Fig. 1 is a graph showing the cell count for in vitro growth of corneal epithelial cells beside scaffolds in accordance with aspects of the present invention; and
Fig. 2 is a graph showing the swelling behaviour of scaffolds in accordance with certain aspects of the invention. Fig. 3 is a graph showing the in vitro growth of DRG nerves (neurites) on selected scaffolds in accordance with aspects of the present invention.
DETAILED DESCRIPTION
Generally, the present invention provides a biocompatible and biodegradable hydrogel scaffold comprising (i) an oxidized polysaccharide, said polysaccharide being selected from the group consisting of chondroitin sulfate, alginate, hyaluronic acid, water- soluble starch and its derivatives, and water-soluble gum and its derivatives, and (ii) an
amine-containing polymer selected from collagen, chitosan, their derivatives, and a mixture thereof, crosslinked to said oxidized polysaccharide.
Depending on the application, the scaffold may gel in vitro or in situ. A hydrogel is a three-dimensional network of hydrophilic polymer chains that are crosslinked through either chemical or physical bonds. Because of the hydrophilic nature of polymer chains, hydrogels absorb water to swell in the presence of abundant water. By definition, water constitutes at least 10% of the total weight (or volume) of a hydrogel. When the content of water exceeds 95% of the total weight (or volume), the hydrogel is called a superabsorbent.
The Oxidized Polysaccharide
The oxidized polysaccharide of the invention may be any of oxidized chondroitin sulfate, alginate, hyaluronic acid, water-soluble starch and its derivatives, or water-soluble gum and its derivatives. The term water-soluble starch includes water-soluble starches that are known to one skilled in the art. Derivatives of water-soluble starches include water-soluble starches that have been oxidized and/or PEGylated.
The term water-soluble gum includes water-soluble gums that are known to one skilled in the art. Examples include xanthan gum, guar gum, dextran gum, acacia gum, carrageenan gum, locust bean gum, and scleroglucan gum. Derivatives of water-soluble gums include water-soluble gums that have been oxidized and/or PEGylated.
The method of preparing the oxidized polysaccharide comprises opening sugar rings on the polysaccharide and oxidizing hydroxyl groups to aldehydes using a selective oxidizing agent. Any selective oxidizing agent, which oxidizes a hydroxyl group to an aldehyde, can be used, such as specific sugar oxidases, sodium periodate, and potassium periodate. In one embodiment sodium periodate or potassium periodate is used. Preferably, the oxidizing agent is one in which a residue thereof would not be harmful to a patient or it can be easily extracted out.
The number of aldehyde groups (AD) produced in this manner can be stoichiometrically controlled, and characterized in terms of oxidation degree (OD), given in mols AD per mol of polysaccharide. A method for determining the degree of oxidation using hydroxylamine hydrochloride titration is provided in Zhao et al., Pharmaceutical Research
8:400-402 (1991 ). For instance, the oxidized polysaccharide may have an OD ranging from 52 to 261 mol aldehyde per mol polysaccharide.
OD may also be stated as % (mol AD/total mol OH) representing:
number of OH groups converted to aldehyde total number of oxidizable OH groups (prior to oxidization).
Thus, for choindroitin sulphate (with a molecular weight of 6OkDa, approximately two oxidizable OH's per repeating unit, and a repeating unit with a molecular weight of 503 Da), an OD of 52 to 261 mol aldehyde per mol polysaccharide is equivalent to approximately 20 to 100% mol AD/total mol.
Oxidizable OH groups include, for instance, adjacent OH groups. Oxidation of adjacent hydroxy! groups is known in the art (see for example, Methods in Carbohydrate Chemistry. 1962 1 : 432-435. Academic Press, New York, Ed. Whistler Wolfrom; and Johann MG Reyes et al. Invest. Ophthalmol. Vis. Sci. 2005 46: 1247-1250).
The oxiized polysaccharide of the invention may have an OD of from 1 to 100%, preferably it has an OD of 20-100%, more preferably 80-100%. Higher ODs (i.e. the more aldehydes) can result in higher the cross-linking density. In turn, when used for sustained release, this will slow down the release rate. Higher ODs also result in slowing down absorption of the hydrogel by the body.
In one aspect the oxidized polysaccharide is an oxidized chondroitin sulphate, also referred to herein as chondroitin sulfate aldehyde (CS-A). Typically, the oxidized chondroitin sulphate is prepared by dissolving chondroitin sulphate and sodium periodate together in deionized water in the dark and allowing them to react for a period of time sufficient to achieve the desired oxidation degree (OD).
Amine-Containing Polymer
The amine-containing polymer is collagen, chitosan, their derivatives, and a mixture thereof. Typically, the average molecular weight of the polymer is about 200 to 600 kDa, but lighter and heavier polymers may be used.
The collagen may be obtained from conventional sources. It may also be a recombinant form, which is particularly useful when very high purity is desirable. The term collagen derivatives includes gelatin.
Chitosan is a linear polysaccharide composed of randomly distributed beta(1 ,4) linked D-glucosamine and N-acetyl-D-glucosamine. The term chitosan includes both acid-soluble and water-soluble chitosan. In one embodiment, the chitosan is acid-soluble chitosan. Chitosan derivatives includes N,O-carboxymethyl chitosan, N-carbosymethyl chitosan, and O-carboxymethyl chitosan, and polyethylene glycol (PEG)-derivatized chitosan.
The amine-containing polymer may be a combination of both chitosan and collagen. The mass ratio of collagen to chitosan may be varied depending on the desired physical and biological characteristics of the scaffold. In one embodiment the mass ratio of collagen to chitosan ranges from 0 to 20, more preferably 1 to 8. The ratio may also be 0 to 8 or 0.5 to 8. In one aspect, the ratio is 4. Typically, if a more transparent and/or homogeneous scaffold is desired, a higher collagen to chitosan mass ratio will be used. Use of a combination of chitosan and collagen results in a hydrogel that has a variety of different functional sites (e.g. -COOH, -OH, -NH2, -CH..etc.), meaning that one has more flexibility in terms of incorporating a variety of drugs, biological agents... etc.
Cross-linking
The aldehyde groups on the oxidized polysaccharides are reacted with the amino groups on the amine-containing polymer, forming covalent imine crosslinks, via a Schiff-base reaction. Generally, the reaction proceeds by cross-linking in aqueous solution at a pH of about 3 to 10. The reaction may also proceed at pH 3-7.4, pH 9-10, or at a pH of 5 or 7.4. The ratios of oxidized polysaccharide to amine-containing polymer can be varied, depending on what physical and biological characteristics are desired. For instance the weight percentage of the oxidized polysaccharide to the amine-containing polymer may be from 5 to 100%, 15 to 95 %, 20 to 30 %, or 24%. In terms of moles of aldehyde in the oxidized polysaccharide to moles of amine in the amine-containing polymer, this may be from about 0.01 to 12, 0.03 to 11 , 0.04 to 3.6, and about 0.75. Scaffolds with a low solid content or high swelling and high water content are preferred for injectable gels; they are also typically more porous. On the other hand, scaffolds with a high solid content, low swelling and low water content are preferred as skin constructs or grafts. High swelling is typically achieved by using less cross-linker (i.e. less of the oxidized polysaccharide, or using a polysaccharide with a lower OD) or using less concentrated solutions of all the reactant. Scaffolds with a lower weight percentage of oxidized polysacchardie to amine-containing polymer are more transparent and homogeneous.
The transparency of the gels may be controlled. The transparency of the scaffold will depend on the chemical composition of the scaffold as well as the pH at which it is made. Typically, in tha basic pH range, the higher the pH, the more transparent the scaffold. All the scaffolds made at pH 9-10 shown in the following examples were clear. The properties of the scaffolds also will depend on the proximal conditions, whether in vitro or in situ.
To make scaffolds in vitro, the oxidized polysaccharide and the amine-containing polymer are mixed together and transferred into a scaffold mold after mixing, and the cross- linking reaction is allowed to proceed. For instance, the scaffolds may cure over a period about 12 to 24 hours at room temperature and for 12 to 24 hours at 37°C. Finally, the scaffolds are washed to extract out any reaction by-products. Sodium cyanoborohydride (Na(CN)BH3) was not used, as it would be toxic if any residue remained in the hydrogel.
To make the scaffolds in situ, the oxidized polysaccharide and the amine-containing polymer are combined together with any desired materials (e.g. cells, growth factors,... etc.), maintained at a temperature well below their phase transition until injection, and then injected into the desired location.
In another aspect, the scaffold excludes constructs comprising hyaluronic acid and only collagen as the polyamine-containing polymer.
Examples
Synthesis of Oxidized Polysaccharide
Example 1.1 : Synthesis of chondroitin sulfate aldehyde with an OD of 52 mol AD/mol
CS (CS-A-52): 4 g of chondroitin sulfate C (Sigma-Aldrich) and 0.5 g of sodium periodate (NaIO4, Sigma-Aldrich) were dissolved together in 66 ml of deionized water and were protected from light. The reaction was allowed to continue for 16 hours in the dark, with vigorous stirring. The insoluble by-products were removed with a 0.45 μrπ filter, and the product was loaded into a dialysis membrane (7 Spectra/Por Membrane, MWCO=2000, OD=29mm) against ddH2O in the shell side by which the product was purified of water-soluble by-products and un-reacted small molecules. The product, CS-aldehyde, was obtained by lyophilization at -65°C for 8 hrs. The determination of the degree of oxidation was performed by hydroxylamine hydrochloride titration (H. Zhao et al., Pharmaceutical Research, 8: 400- 402 (1991 )). The OD was determined as 52 mol AD/mol CS.
Example 1.2: Synthesis of chondroitin sulfate aldehyde with an OD of 94 mol AD/mol CS (CS-A-94): Two grams of chondroitin sulfate C (CS, Sigma-Aldrich) and 2 g of sodium periodate (NaIO4, Sigma-Aldrich) were dissolved together in 33 ml of deionized water and were protected from light. The reaction was processed as for Example 1.1. The OD was determined as 94 mol AD/mol CS.
Example 1.3: Synthesis of Chondroitin Sulfate Aldehyde with an OD of 261 mol AD/mol CS (CS-A-261): Two grams of chondroitin sulfate C (CS, Sigma-Aldrich) and 4 g of sodium periodate (NaIO4, Sigma-Aldrich) were dissolved together in 33 ml of deionized water and were protected from light. The reaction was processed as for Example 1.1. The OD was determined as 261 mol AD/mol CS.
Preparation of Amine-Containing Polymers Example 1.4: Preparation of Solutions of Chitosan, Collagen, and mixtures thereof :
Solutions of amine-containing polymers were prepared. Chitosan solutions were prepared containing 2-10% (w/v) chitosan by dissolving chitosan flakes (Mw 40OkDa obtained from Fluka) in 0.2 N hydrochloric acid (HCI) and stirring at 40C. Collagen solutions were prepared containing 1-20% (w/v) collagen type I; freeze dried porcine collagen powder that was obtained from Nippon Meat Packers, lnc (Japan) was dissolved in cold water (sterile dd H2O) and stirred at 4°C. Mixtures of chitosan and collagen were prepared by mixing the above mentioned solutions of chitosan and collagen together in a syringe system at predetermined ratios to make a homogeneous blend containing 2-10% (w/v) chitosan and 1-20% (w/v) collagen type I.
Preparation of Scaffolds
Various scaffolds in accordance with aspects of the invention are shown in Table 1. The w/v %'s given for the acid-soluble chitosan and the collagen columns refer to pre-mixing %'s. The collagen to chitosan mass ratio refers to the ratios upon mixing and throughout the crosslinking reaction.
The amine-containing polymers were cross-linked using chondroitin sulfate aldehyde (CS-A). Generally, the 200 series scaffolds (collagen concentration ranges from 2-20% w/v) were prepared by mixing the amine-containing polymer with the oxidized polysaccharide (the
crosslinker) at a pH of about 3 using 0.6 M 2-(N-Morpholino) ethanesulfunic acid (MES) buffer or a pH of about 5 to 7.4 using sodium hydroxide or various concentrations of phosphate buffered saline (PBS). The 300 series scaffolds (collagen concentration is 1% w/v) were prepared as described.
Example 2.1 : Preparation of BCI-206 scaffold: 1 ml of 5% chitosan solution was transferred to a 2.5 ml Luer tip glass syringe. The chitosan solution was then mixed with 0.3 ml MES buffer using a plastic Tefzel Tee-piece. The mixture was then mixed with 0.0181 g CS-A-261 cross-linker agent [CS-A to chitosan mass ratio of 0.31] that was dissolved in 0.2 ml MES buffer, at about 0°C-4°C. The components were thoroughly mixed by repeated pumping action between the first and second syringes through the Tee. This process was performed under iced water to prevent premature crosslinking and air bubbles formation and entrapment.
The homogeneous mixture was immediately dispensed into 500 microns glass flat moulds (or plastic in vitro moulds) and cured first at room temperature for 24 hours, and then at 370C for 24 hours, in 100% humidity environments at both temperatures. Each final scaffold sample was carefully separated from its mould after immersion in phosphate buffered saline (PBS) for 1 hour. Finally, the cross-linked scaffolds were immersed in PBS solution (0.5% in PBS, containing 1 % chloroform) at room temperature to extract out reaction by-products.
Example 2.2: Preparation of BCI-207 scaffold: This scaffold was prepared as for Example 2.1 using 1 ml of 5% chitosan solution and 0.0091 g CS-A-261 cross-linker agent [CS-A to chitosan mass ratio of 0.18].
Example 2.3: Preparation of BCI-210 scaffold: This scaffold was prepared as for Example 2.1 using 1 ml of 5% chitosan solution and 0.0091 g CS-A-52 cross-linker agent [CS-A to chitosan mass ratio of 0.18].
Example 2.4: Preparation of BCI-211 scaffold: 0.5 ml of 5% chitosan solution was added to 0.25 ml of a 4% collagen solution [collagen:chitosan mass ratio of 0.5] in a 2.5 ml Luer tip glass syringe. The composition was then mixed with 0.35 ml MES buffer (or PBS buffer) using a plastic Tefzel™ Tee-piece. The mixture was then mixed with 0.0141 g CS-A-261
cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.47] that was dissolved in 0.35 ml MES buffer (or PBS buffer), at about 0°C-4°C. The remainder of the reaction was processed as for Example 2.1.
Example 2.5: Preparation of BCI-212 scaffold: This scaffold was prepared as for Example 2.4 using 0.25 ml of 5% chitosan solution and 0.5 ml of a 4% collagen solution [collagen:chitosan mass ratio of 2.0] and 0.0072 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.18].
Example 2.6: Preparation of BCI-213 scaffold: This scaffold was prepared as for
Example 2.4 using 0.5 ml of 5% chitosan solution and 0.25 ml of a 4% collagen solution [collagen:chitosan mass ratio of 0.5] and 0.0282 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.94], which was synthesized according to Example 1.3.
Example 2.7: Preparation of BCI-214 scaffold: This scaffold was prepared as for
Example 2.4 using 0.25 ml of 5% chitosan solution and 0.5 ml of a 4% collagen solution [collagen:chitosan mass ratio of 2.0] and 0.0145 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.51].
Example 2.8: Preparaton of BCI-217 scaffold: 0.7 ml of 4% collagen solution was transferred to a 2.5 ml Luer tip glass syringe. The collagen solution was then mixed with 0.3 ml MES buffer using a plastic Tefzel Tee-piece. The mixture was then mixed with 0.0193 g CSA-261 cross-linker agent [CSA to collagen mass ratio of 0.69] that was dissolved in 0.3 ml MES buffer, at about 0°C-4°C. The remainder of the reaction was processed as for Example 2.1.
Example 2.9: Preparation of BCI-218 scaffold: 0.17 ml of 5% chitosan solution was added to 0.75 ml of a 4% collagen solution [collagen:chitosan mass ratio of 4.2] in a 2.5 ml Luer tip glass syringe. The composition was then mixed with 0.3 ml MES buffer (or PBS buffer) using a plastic Tefzel Tee-piece. The mixture was then mixed with 0.0089 g CS-A-261 cross-linker agent [CS-A to chitosan/collagen mass ratio of 0.24] that was dissolved in 0.3 ml MES buffer (or PBS buffer), at about 0°C-4°C. The remainder of the reaction was processed as for Example 2.1.
Example 2.10: Preparation of BC I -221 scaffold: This scaffold was prepared as for Example 2.9 using 0.145 ml of 3% chitosan solution and 0.75 ml of a 2% collagen solution [collagen:chitosan mass ratio of 4.2] and 0.0092 g CSA-261 cross-linker agent [CSA to chitosan/collagen mass ratio of 0.49].
Example 2.11 : Preparation of BCI-222 scaffold: This scaffold was prepared as for Example 2.9 using 0.3 ml of 5% chitosan solution and 0.50 ml of a 20% collagen solution [collagen:chitosan mass ratio of 8.0] and 0.0184 g CSA-261 cross-linker agent [CSA to chitosan/collagen mass ratio of 0.16].
Example 3.1 : Preparation of BCI-300 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial. This vial was cooled on ice for 30min. 200μl of CSA-52 (12 mg CSA/ml water) was added causing a translucent gel to be formed. The final pH of the mixture was 4. The gel was incubated for a further 15h at room temperature and washed with water.
Example 3.2: Preparation of BCI-301 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial. This vial was cooled on ice for 30min. 50μl of CSA-52 (12mg CSA/ml water) was added causing a translucent gel to be formed. The final pH of the mixture was 4. The gel was incubated for a further 15h at room temperature and washed with water.
Example 3.3: Preparation of BCI-302 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial, and this vial was cooled on ice for 30min. Then 10μl NaOH (2N) was added and mixed. 200μl of CSA-52 (12mg CSA/ml water) was added, forming a transparent gel. The final pH of the gelling mixture was 10. The gel was incubated for a further 15h at room temperature and then washed with water overnight.
Example 3.4: Preparation of BCI-303 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial, and the vial was cooled on ice for 30min. 10μl NaOH (2N) was added and mixed. Then, 30μl of CSA-94 (22.67mg CSA/ml water) was added forming a transparent gel. The final pH of the gelling mixture was 10. The gel was incubated for a further 15h at room temperature and then washed with water overnight.
Example 3.5: Preparation of BC I -304 scaffold: 1 ml of 1 % type I collagen was added to a 4 ml vial, and the vial was cooled on ice for 30min. 10μl NaOH (2N) was added and mixed. Then, 150 μl of CSA-94 (22.67mg CSA/ml water) was added forming a transparent gel. The final pH of the gelling mixture was 10. The gel was incubated for a further 15h at room temperature and then washed with water overnight.
Table 1: Summary of compositions for chitosan/collagen/cs.ald scaffolds
NPM: Collagen suppliers name: Nippon Meat Packers, Inc, Japan * CS-ald: Chondroitin sulfate aldehyde OD: Oxidation degree (mole CHOs per mole CS) : CHO to NH2 molar ratio: The NH2 refers to the total amount of calculated NH2 in chitosan and the NH2 of lysine residuals in collagen
Example 4: Growth of human corneal epithelial cells (HCEC) on the invented materials for cytotoxicity evaluation (In Vitro Biocompatibility Assessment): The scaffolds produced according to Examples 2 and 3 were assessed to determine the short-term (7 days) biocompatibility of the scaffolds with respect to the HCEC line. Scaffolds were washed 2 x 3 hours in PBS and treated with antibiotics for 24 hours. Scaffolds were cut into pieces if necessary and placed on the bottom of a 24-well tissue culture plate (n=3). Human corneal epithelial cells (passage #1235) were seeded at a density of 5x103 cells per scaffold in KSFM culture medium (Invitrogen Cat# 17005-042) supplemented with 1x penicillin/streptomycin (Sigma Cat# P4333). Cultures were photographed on Days 2, 4 and 7 post-seeding. Quantified results were obtained by analyzing all photographs. An area of scaffold was selected for counting, and viable-looking cells within that area were counted using Northern Eclipse 6.0 software. The number of cells counted was normalized to the area of scaffold selected, and multiplied by a constant. The counts were expressed as cells per unit surface area. In order to see the cells and morphology of the cells' nuclei 4'-6-Diamidino- 2-phenylindole (DAPI) staining was used for less transparent scaffolds. All materials supported excellent or good cell growth on and beside the scaffolds compared to culture dish control surfaces. They were all confluent by Day 7.
The number of epithelial cells beside the scaffolds were quantified for days two, four, and seven post-seeding and shown in Figure 1. As we can see in this Figure, growth rate of the cells was found to be similar and comparable to the control. A confluent epithelium was observed for all scaffolds and control on day 7.
Example 5: Water Uptake (Swelling) Test: The scaffolds were tested to determine their swelling properties with respect to a PBS solution. The swelling behaviour of the scaffolds was measured by swelling the dry scaffolds in phosphate buffered saline (1 % PBS) media. Scaffolds were dried by placing them in cold chamber purged by filtered dry air at 4 0C. Pre- weighed dry hydrogel films were then immersed in buffer solutions at pH 7.4 at room temperature. The immersion time was 24 hrs. The films were withdrawn from the solution and their wet weights were determined after first blotting with a filter paper to remove the surface water and immediately weighing the films. The swelling ratio was calculated using the equation:
Sf? (w%) = ((WS - Wd) / Wd) * 100 (1)
where SR represents the water absorption or uptake (w%) of the films, Wd and Ws are the weights of the samples in the dry and swollen states, respectively.
The crosslinking index (Cl) was defined and calculated from the following equation:
C/ = (1/SR) x 700 (2)
where Cl represents the cross-linking Index or extend of crosslinking.
The solid content was also determined using the following equation:
SC (w%) = (W d / Ws) x 700 (3)
All swelling behaviours of scaffolds are plotted on the average of three trials in Figure 2. The BCI-12 scaffold had the highest swelling ratio and the lowest crosslinking index (Cl), while BCI-13 had the lowest swelling ratio and the highest crosslinking index. These results are in good agreement with the concentration of the crosslinking agent (CHCVNH2 ratio) as summarized in Table 1. The lower the crosslinking agent concentration, the lower was the Cl and the higher was the swelling ratio. All scaffolds exhibited high degree of swelling behaviour specific to hydrogels.
Example 6: Evaluation of surface neurite extension of dorsal root ganglia (DRG) on scaffolds: Selected scaffolds were tested for in vitro biocompatibility to nerve cells using dorsal root ganglia (DRG) from chick embryos (E 8.0). DRGs were isolated from 8 day old chick embryos and adhered to the surface of washed hydrogels with collagen matrix. DRGs were then covered with DRG medium. Neuhtes were grown for a total of 7 days, with DRG medium being changed for every 2 days. Samples were fixed on day 7 post-adhering using 4% paraformaldehyde followed by staining at 4°C overnight for the presence of neurofilament using mouse anti-NF200 antibody (Sigma Cat# N5389) diluted 1 :40 in TCT. Neurofilaments were visualized the following day using donkey anti-mouse-Cy2 (Amersham Pharmacia Cat# PA42002, 1 :200 in TCT). Whole-mounts were imaged using an Axiovert microscope. As shown in Fig. 3, DRG nerve overgrowth was observed for BCI-221 , and BCI-218 scaffolds. Despite the capability of BCI-221 and culture dish control, BCI-218 better supported the nerve cells and DRG neuritis.
All references referred to herein are hereby incorporated by reference.
The above-described embodiments of the present invention are intended to be examples only. Alterations, modifications and variations may be effected to the particular embodiments by those of skill in the art without departing from the scope of the invention, which is defined solely by the claims appended hereto.
Claims
1. A biocompatible and biodegradable hydrogel scaffold comprising:
an oxidized polysaccharide, said polysaccharide being selected from the group consisting of chondroitin sulfate, alginate, hyaluronic acid, water-soluble starch and its derivatives, and water-soluble gum and its derivatives, and
an amine-containing polymer selected from collagen, chitosan, their derivatives, and a mixture thereof, crosslinked to said oxidized polysaccharide.
2. The scaffold of claim 1 , wherein the oxidized polysaccharide is oxidized chondroitin sulfate.
3. The scaffold of claim 2, wherein the amine-containing polymer is collagen, chitosan, or a mixture thereof.
4. The scaffold of claim 1 , wherein the oxidized polysaccharide is oxidized chondrointin sulfate and the amine-containing polymer is a mixture of collagen and chitosan.
5. The scaffold of any one of claims 1 to 4, wherein the oxidized polysaccharide has an oxidation degree of 1 to 100%, 20 to 100%, or 80 to 100%.
6. The scaffold of any one of claims 1 to 5, wherein the weight percentage of the oxidized polysaccharide to the amine-containing polymer is from 5 to 100%, 15 to 95 %, 20 to 30 %, or 24%.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86861806P | 2006-12-05 | 2006-12-05 | |
US60/868,618 | 2006-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008067655A1 true WO2008067655A1 (en) | 2008-06-12 |
Family
ID=39491611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2007/002179 WO2008067655A1 (en) | 2006-12-05 | 2007-12-05 | Biocompatible hydrogel-based scaffolds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008067655A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009132227A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Protective gel based on chitosan and oxidized polysaccharide |
EP1691820A4 (en) * | 2003-11-08 | 2010-03-03 | Prothera Biolog | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
WO2012068619A1 (en) * | 2010-11-23 | 2012-05-31 | Elastagen Pty Ltd | Preparation and/or formulation of proteins cross-linked with polysaccharides |
US8530632B2 (en) | 2008-04-24 | 2013-09-10 | Medtronic Xomed, Inc. | Chitosan-containing protective composition |
WO2014072035A1 (en) * | 2012-11-07 | 2014-05-15 | Eth Zurich | Sulfated alginate hydrogels for cell culture and therapy |
US8809301B2 (en) | 2007-08-28 | 2014-08-19 | Adelaide Research & Innovation Pty Ltd | Surgical hydrogel |
KR20150069992A (en) * | 2013-12-13 | 2015-06-24 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | Biodegradable medical adhesive or sealant compositions |
US9139641B2 (en) | 2008-05-28 | 2015-09-22 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha proteins from blood |
US9198997B2 (en) | 2008-04-24 | 2015-12-01 | Medtronic, Inc. | Rehydratable thiolated polysaccharide particles and sponge |
US9561248B2 (en) | 2008-04-24 | 2017-02-07 | Medtronic, Inc. | Method for rehydrating polysaccharide particles |
US9572872B2 (en) | 2012-09-09 | 2017-02-21 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
WO2018042405A1 (en) * | 2016-09-05 | 2018-03-08 | A4Tec - Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec | Kefiran for use in regenerative medicine and/or tissue engineering |
CN111714694A (en) * | 2019-05-30 | 2020-09-29 | 四川大学 | Collagen-based cell scaffold with angiogenesis promoting performance and preparation method thereof |
CN111732737A (en) * | 2020-06-16 | 2020-10-02 | 武汉工程大学 | Degradable self-healing chitosan composite aldehyde guar gum gel and preparation method and application thereof |
CN113164650A (en) * | 2018-11-30 | 2021-07-23 | 株式会社 Nextbiomedical | Hydrogel particles for chemoembolization comprising biodegradable macromolecules |
CN113185714A (en) * | 2021-04-16 | 2021-07-30 | 江南大学 | High-adhesion antibacterial healing-promoting hydrogel and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866165A (en) * | 1997-01-15 | 1999-02-02 | Orquest, Inc. | Collagen-polysaccharide matrix for bone and cartilage repair |
US6514522B2 (en) * | 1998-04-08 | 2003-02-04 | Chondros, Inc. | Polymer constructs |
US20040044416A1 (en) * | 2000-12-28 | 2004-03-04 | Lanfranco Callegaro | Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preperation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy |
CA2520398A1 (en) * | 2003-03-27 | 2004-10-07 | Regentec Limited | Two phase porous matrix for use as a tissue scaffold |
-
2007
- 2007-12-05 WO PCT/CA2007/002179 patent/WO2008067655A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866165A (en) * | 1997-01-15 | 1999-02-02 | Orquest, Inc. | Collagen-polysaccharide matrix for bone and cartilage repair |
US6514522B2 (en) * | 1998-04-08 | 2003-02-04 | Chondros, Inc. | Polymer constructs |
US20040044416A1 (en) * | 2000-12-28 | 2004-03-04 | Lanfranco Callegaro | Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preperation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy |
CA2520398A1 (en) * | 2003-03-27 | 2004-10-07 | Regentec Limited | Two phase porous matrix for use as a tissue scaffold |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1691820A4 (en) * | 2003-11-08 | 2010-03-03 | Prothera Biolog | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
USRE47972E1 (en) | 2003-11-08 | 2020-05-05 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
EP3087991A1 (en) * | 2003-11-08 | 2016-11-02 | Prothera Biologics | Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
US8809301B2 (en) | 2007-08-28 | 2014-08-19 | Adelaide Research & Innovation Pty Ltd | Surgical hydrogel |
US9333220B2 (en) | 2008-04-24 | 2016-05-10 | Medtronic, Inc. | Method for treating the ear, nose, sinus or throat |
US8530632B2 (en) | 2008-04-24 | 2013-09-10 | Medtronic Xomed, Inc. | Chitosan-containing protective composition |
US10420794B2 (en) | 2008-04-24 | 2019-09-24 | Medtronic, Inc. | Polysaccharide particle mixture |
US9561248B2 (en) | 2008-04-24 | 2017-02-07 | Medtronic, Inc. | Method for rehydrating polysaccharide particles |
CN102065849B (en) * | 2008-04-24 | 2015-04-29 | 麦德托尼克公司 | Protective gel based on chitosan and oxidized polysaccharide |
US9433636B2 (en) | 2008-04-24 | 2016-09-06 | Medtronic, Inc. | Protective gel based on chitosan and oxidized polysaccharide |
WO2009132227A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Protective gel based on chitosan and oxidized polysaccharide |
US9198997B2 (en) | 2008-04-24 | 2015-12-01 | Medtronic, Inc. | Rehydratable thiolated polysaccharide particles and sponge |
US9139641B2 (en) | 2008-05-28 | 2015-09-22 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha proteins from blood |
US10076559B2 (en) | 2008-05-28 | 2018-09-18 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha inhibitor proteins from blood |
US9758570B2 (en) | 2008-05-28 | 2017-09-12 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha inhibitor proteins from blood |
AU2021201321C1 (en) * | 2010-11-23 | 2023-06-01 | Allergan Pharmaceuticals International Limited | Preparation and/or formulation of proteins cross-linked with polysaccharides |
AU2021201321B2 (en) * | 2010-11-23 | 2023-02-02 | Allergan Pharmaceuticals International Limited | Preparation and/or formulation of proteins cross-linked with polysaccharides |
US11065365B2 (en) | 2010-11-23 | 2021-07-20 | Allergan Pharmaceuticals International Limited | Preparation and/or formulation of proteins cross-linked with polysaccharides |
US10653814B2 (en) | 2010-11-23 | 2020-05-19 | Allergan Pharmaceuticals International Limited | Preparation and/or formulation of proteins cross-linked with polysaccharides |
JP2017008051A (en) * | 2010-11-23 | 2017-01-12 | エラスタジェン ピーティーワイ リミテッドElastagen Pty Ltd | Preparation and/or formulation of proteins cross-linked with polysaccharides |
JP2013544593A (en) * | 2010-11-23 | 2013-12-19 | エラスタジェン ピーティーワイ リミテッド | Preparation and / or formulation of proteins cross-linked by polysaccharides |
WO2012068619A1 (en) * | 2010-11-23 | 2012-05-31 | Elastagen Pty Ltd | Preparation and/or formulation of proteins cross-linked with polysaccharides |
US9611312B2 (en) | 2010-11-23 | 2017-04-04 | Elastagen Pty. Limited | Preparation and/or formulation of proteins cross-linked with polysaccharides |
CN103384537A (en) * | 2010-11-23 | 2013-11-06 | 艾拉斯塔根私人有限公司 | Preparation and/or formulation of proteins cross-linked with polysaccharides |
CN107281549A (en) * | 2010-11-23 | 2017-10-24 | 艾拉斯塔根私人有限公司 | The preparation for the protein being crosslinked with polysaccharide and/or preparation |
US9572872B2 (en) | 2012-09-09 | 2017-02-21 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
US10258675B2 (en) | 2012-09-09 | 2019-04-16 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
EP3656405A1 (en) * | 2012-11-07 | 2020-05-27 | ETH Zürich | Sulfated alginate hydrogels for cell culture and therapy |
WO2014072035A1 (en) * | 2012-11-07 | 2014-05-15 | Eth Zurich | Sulfated alginate hydrogels for cell culture and therapy |
US9937257B2 (en) | 2012-11-07 | 2018-04-10 | Eth Zurich | Sulfated alginate hydrogels for cell culture and therapy |
US10980887B2 (en) | 2012-11-07 | 2021-04-20 | Eth Zurich | Sulfated alginate hydrogels for cell culture and therapy |
US20160317702A1 (en) * | 2013-12-13 | 2016-11-03 | Utah-Inha Dds & Advanced Therapeutics Research Center | Biodegradable medical adhesive or sealant composition |
JP2017500113A (en) * | 2013-12-13 | 2017-01-05 | ユタ−イナ ディーディーエス アンド アドバンスト セラピューティクス リサーチ センター | Biodegradable medical adhesive or sealant composition |
KR20150069992A (en) * | 2013-12-13 | 2015-06-24 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | Biodegradable medical adhesive or sealant compositions |
EP3081236A4 (en) * | 2013-12-13 | 2017-08-16 | Utah-Inha DDS & Advanced Therapeutics Research Center | Biodegradable medical adhesive or sealant composition |
US10105465B2 (en) * | 2013-12-13 | 2018-10-23 | Utah-Inha Dds & Advanced Therapeutics Research Center | Biodegradable medical adhesive or sealant composition |
KR101664444B1 (en) | 2013-12-13 | 2016-10-12 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | Biodegradable medical adhesive or sealant compositions |
WO2018042405A1 (en) * | 2016-09-05 | 2018-03-08 | A4Tec - Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec | Kefiran for use in regenerative medicine and/or tissue engineering |
CN113164650A (en) * | 2018-11-30 | 2021-07-23 | 株式会社 Nextbiomedical | Hydrogel particles for chemoembolization comprising biodegradable macromolecules |
CN111714694A (en) * | 2019-05-30 | 2020-09-29 | 四川大学 | Collagen-based cell scaffold with angiogenesis promoting performance and preparation method thereof |
CN111714694B (en) * | 2019-05-30 | 2021-04-06 | 四川大学 | Collagen-based cell scaffold with angiogenesis promoting performance and preparation method thereof |
CN111732737A (en) * | 2020-06-16 | 2020-10-02 | 武汉工程大学 | Degradable self-healing chitosan composite aldehyde guar gum gel and preparation method and application thereof |
CN113185714A (en) * | 2021-04-16 | 2021-07-30 | 江南大学 | High-adhesion antibacterial healing-promoting hydrogel and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008067655A1 (en) | Biocompatible hydrogel-based scaffolds | |
Pandit et al. | Periodate oxidized hyaluronic acid-based hydrogel scaffolds for tissue engineering applications | |
Nezhad-Mokhtari et al. | A review on the construction of hydrogel scaffolds by various chemically techniques for tissue engineering | |
Tan et al. | Controlled gelation and degradation rates of injectable hyaluronic acid‐based hydrogels through a double crosslinking strategy | |
Wu et al. | Chitosan-based composite hydrogels for biomedical applications | |
Zhou et al. | Glycerophosphate-based chitosan thermosensitive hydrogels and their biomedical applications | |
CA2512730C (en) | Hydroxyphenyl cross-linked macromolecular network and applications thereof | |
CN108697805B (en) | Temperature-sensitive hydrogel composition containing nucleic acid and chitosan | |
KR101966555B1 (en) | Biocompatible hydrogel and method for preparing the same | |
US6790840B1 (en) | Reversibly cross-linked hydrogels | |
JP5746617B2 (en) | Injectable hydrogel forming a chitosan mixture | |
WO2006118461A2 (en) | Modular bioresorbable or biomedical, biologically active supramolecular materials | |
Wang et al. | Dual-enzymatically crosslinked and injectable hyaluronic acid hydrogels for potential application in tissue engineering | |
US20130045242A1 (en) | Dextrin hydrogel for biomedical applications | |
EP0977780B1 (en) | Hetero-polysaccharide conjugates, s-inp polysaccharide gels and methods of making and using the same | |
CN1830420B (en) | Injection type pH sepsitive chitin quarternary ammonium salt aquagel and its preparation method | |
WO2007058539A2 (en) | Modular supramolecular materials for biomedical uses | |
US9867909B2 (en) | Multilayer implants for delivery of therapeutic agents | |
CN112587726B (en) | Composite hydrogel stent and preparation method and application thereof | |
CN115429935B (en) | Injectable cross-linked chondroitin sulfate hydrogel and preparation method thereof | |
EP4198060A1 (en) | Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same | |
CN111333869A (en) | Preparation method of degradable sustained-release gel for resisting novel coronavirus | |
Ruso et al. | Application of natural, semi-synthetic, and synthetic biopolymers used in drug delivery systems design | |
KR20230123959A (en) | Implantable device using chemically cross-linked alginic acid | |
CN112972434A (en) | Preparation method of hydrophilic drug-loaded composite fiber membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07855461 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS TO RULE 112(1) EPC DATED 28.09.09 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07855461 Country of ref document: EP Kind code of ref document: A1 |